Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Drug attack on Hard-to-Treat stomach cancer shows promise in early trial

NCT ID NCT07176312

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer from growing for at least 12 months. All participants receive the same treatment, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Zanidatamab (a targeted antibody), pembrolizumab (an immunotherapy), and chemotherapy (mFOLFOX)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with HER2 and PD-L1 positive metastatic gastroesophageal cancer, potentially improving how long they live without the disease getting worse.
What could go wrong
This is an early Phase II trial with only 80 participants and no comparison group, so results may not be definitive. The combination of three drugs may cause significant side effects, and not all patients will respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST LINE THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm gastroesophageal adenocarcinoma metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST LINE THERAPY GASTROESOPHAGEAL ADENOCARCINOMA HER2 + GASTRIC CANCER METASTASES PDL-1

Contacts and locations

Locations

  • Asklepios Klinik Altona

    RECRUITING

    Hamburg, Germany

  • Charité CVK

    RECRUITING

    Berlin, Germany

  • Evang. Kliniken Essen Mitte

    RECRUITING

    Essen, Germany

  • Hämatologisch Onkologische Praxis Eppendorf (HOPE)

    RECRUITING

    Hamburg, 20249, Germany

    Contact Email: •••••@•••••

  • Johannes Wesling Klinikum Minden

    NOT_YET_RECRUITING

    Minden, Germany

  • Klinikum Bielefeld

    RECRUITING

    Bielefeld, Germany

  • Klinikum Wolfsburg

    NOT_YET_RECRUITING

    Wolfsburg, Germany

  • Klinikum rechts der Isar der TU München

    RECRUITING

    München, Germany

  • Krankenhaus Barmherzige Brüder Regensburg

    RECRUITING

    Regensburg, Germany

  • Krankenhaus Nordwest

    RECRUITING

    Frankfurt, Germany

  • LMU Klinikum München Großhadern

    NOT_YET_RECRUITING

    München, Germany

  • MVZ für Hämatologie und Onkologie Ravensburg

    RECRUITING

    Ravensburg, Germany

  • St. Anna Hospital Herne

    RECRUITING

    Herne, Germany

  • Städtisches Klinikum Dresden

    NOT_YET_RECRUITING

    Dresden, Germany

  • Universitätsklinikum Göttingen

    NOT_YET_RECRUITING

    Göttingen, Germany

  • Universitätsklinikum Hamburg Eppendorf

    RECRUITING

    Hamburg, Germany

  • Universitätsklinikum Jena

    RECRUITING

    Jena, Germany

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, Germany

  • Universitätsmedizin Mainz

    NOT_YET_RECRUITING

    Mainz, Germany

  • Vivantes Klinikum im Friedrichshain

    RECRUITING

    Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.